Trilogy Capital Inc. Has $2.75 Million Stake in Amgen Inc. (NASDAQ:AMGN)

Trilogy Capital Inc. decreased its position in shares of Amgen Inc. (NASDAQ:AMGNFree Report) by 6.5% in the 4th quarter, Holdings Channel reports. The fund owned 9,560 shares of the medical research company’s stock after selling 665 shares during the quarter. Trilogy Capital Inc.’s holdings in Amgen were worth $2,754,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Claro Advisors LLC raised its holdings in shares of Amgen by 6.9% during the 2nd quarter. Claro Advisors LLC now owns 1,868 shares of the medical research company’s stock valued at $415,000 after buying an additional 120 shares in the last quarter. Fuller & Thaler Asset Management Inc. increased its stake in Amgen by 1.7% in the 3rd quarter. Fuller & Thaler Asset Management Inc. now owns 11,658 shares of the medical research company’s stock worth $3,133,000 after purchasing an additional 193 shares during the period. Reuter James Wealth Management LLC increased its stake in Amgen by 48.0% in the 2nd quarter. Reuter James Wealth Management LLC now owns 4,363 shares of the medical research company’s stock worth $969,000 after purchasing an additional 1,416 shares during the period. Nicolet Advisory Services LLC increased its stake in Amgen by 4.4% in the 3rd quarter. Nicolet Advisory Services LLC now owns 2,805 shares of the medical research company’s stock worth $745,000 after purchasing an additional 117 shares during the period. Finally, Fortune Financial Advisors LLC purchased a new position in Amgen in the 2nd quarter worth approximately $230,000. 74.44% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, SVP Nancy A. Grygiel sold 2,096 shares of the business’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $273.03, for a total value of $572,270.88. Following the completion of the transaction, the senior vice president now owns 10,874 shares in the company, valued at $2,968,928.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.57% of the company’s stock.

Amgen Stock Down 0.4 %

Amgen stock traded down $1.03 during mid-day trading on Wednesday, hitting $277.46. The company had a trading volume of 3,026,313 shares, compared to its average volume of 3,012,291. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 10.14. The stock’s 50 day moving average price is $298.32 and its two-hundred day moving average price is $278.24. Amgen Inc. has a 12 month low of $211.71 and a 12 month high of $329.72. The company has a market capitalization of $148.70 billion, a PE ratio of 22.25, a price-to-earnings-growth ratio of 2.78 and a beta of 0.62.

Amgen (NASDAQ:AMGNGet Free Report) last released its earnings results on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, topping the consensus estimate of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The business had revenue of $8.20 billion for the quarter, compared to the consensus estimate of $8.13 billion. During the same period in the previous year, the company posted $4.09 earnings per share. The company’s revenue for the quarter was up 19.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that Amgen Inc. will post 19.51 earnings per share for the current fiscal year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 7th. Shareholders of record on Friday, February 16th will be issued a $2.25 dividend. This represents a $9.00 annualized dividend and a yield of 3.24%. This is an increase from Amgen’s previous quarterly dividend of $2.13. The ex-dividend date of this dividend is Thursday, February 15th. Amgen’s payout ratio is 72.06%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Oppenheimer reaffirmed an “outperform” rating and issued a $350.00 price target on shares of Amgen in a research note on Thursday, February 1st. SVB Leerink cut Amgen from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $324.00 to $318.00 in a research note on Wednesday, February 7th. Royal Bank of Canada lifted their price objective on Amgen from $303.00 to $329.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. StockNews.com lowered Amgen from a “buy” rating to a “hold” rating in a research report on Friday, February 16th. Finally, UBS Group cut their price objective on Amgen from $315.00 to $314.00 and set a “neutral” rating on the stock in a research report on Monday, January 29th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $295.30.

View Our Latest Stock Analysis on Amgen

Amgen Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Further Reading

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.